Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting
Coronary Artery Disease, Myocardial Ischemia, Heart Diseases
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring MICS CABG OPCABG ONCABG CAD
Eligibility Criteria
Inclusion Criteria:
- Multi-vessel coronary artery disease with ≥ 70% artery stenosis (according to QCA)
- II-IV Canadian Cardiovascular Society functional class of angina
- Patients at 1 month after acute myocardial infarction
- Ability to perform either of revascularization methods (MICS CABG, OPCABG, ONCABG)
- Patients must have signed an informed consent
Exclusion Criteria:
- Pregnancy.
- Acute coronary syndrome.
- Previous CABG.
- Severe comorbidity with high procedural risk for either of the studied strategies.
- Mental diseases which block the revascularization procedure.
- Severe peripheral artery disease.
- Other serious diseases limiting life expectancy (e.g. oncology)
- Inability for long-term follow-up.
- Participation in other clinical trials.
- Single vessel disease.
- Need for emergency revascularization (Acute MI, Acute coronary syndrome etc.)
Sites / Locations
- Vitebsk regional clinical hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
MICS CABG
OPCABG
ONCABG
Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt. (MICS CABG group, n=50)
Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt. (OPCABG group, n=50)
On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)